Reduction of radioantibody-induced myelotoxicity in hamsters by recombinant interleukin-1.
Recombinant human interleukin 1 (IL-1) administered i.p. to tumor-bearing hamsters results in a dose-dependent 2- to 5-fold increase in total peripheral white blood cells. These levels remain elevated for 2 to 3 wk and then decline to base-line levels. Pretreatment of animals with similar doses of IL-1 prevents radioimmunotherapy-induced destruction of the radiosensitive hematopoietic system. Furthermore, recovery from radio-immunotherapy-induced myelosuppression is possible if animals are given IL-1 1 wk after radioimmunotherapy treatment. Thus, both protection and rescue from the hematopoietic damage associated with radioantibody treatment are feasible by pre- or posttreatment with IL-1.
Blumenthal
R D
RD
Center for Molecular Medicine and Immunology, University of Medicine and Dentistry of New Jersey, Newark 07103.
Sharkey
R M
RM
Snyder
D J
DJ
Hansen
H J
HJ
Goldenberg
D M
DM
D000818:Animals; D001853:Bone Marrow / Q000187:drug effects*; D006224:Cricetinae; D004305:Dose-Response Relationship, Drug; D005260:Female; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D007116:Immunization, Passive; D000922:Immunotoxins / Q000627:therapeutic use*; D007375:Interleukin-1 / Q000633:toxicity*; D007958:Leukocyte Count; D008647:Mesocricetus; D011994:Recombinant Proteins / Q000633:toxicity
D000922:Immunotoxins; D007375:Interleukin-1; D011994:Recombinant Proteins